- Home
- RDVT vs CGEM Comparison
RDVT vs CGEM Comparison
Compare RDVT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- CGEM
- Stock Information
- Founded
- RDVT 2017
- CGEM 2016
- Country
- RDVT United States
- CGEM United States
- Employees
- RDVT N/A
- CGEM N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- RDVT Technology
- CGEM Health Care
- Exchange
- RDVT Nasdaq
- CGEM Nasdaq
- Market Cap
- RDVT 538.6M
- CGEM 506.1M
- IPO Year
- RDVT N/A
- CGEM 2021
- Fundamental
- Price
- RDVT $36.75
- CGEM $7.53
- Analyst Decision
- RDVT Strong Buy
- CGEM Strong Buy
- Analyst Count
- RDVT 1
- CGEM 8
- Target Price
- RDVT $25.00
- CGEM $32.86
- AVG Volume (30 Days)
- RDVT 78.7K
- CGEM 416.8K
- Earning Date
- RDVT 05-07-2025
- CGEM 05-14-2025
- Dividend Yield
- RDVT 0.80%
- CGEM N/A
- EPS Growth
- RDVT N/A
- CGEM N/A
- EPS
- RDVT 0.50
- CGEM N/A
- Revenue
- RDVT $75,189,000.00
- CGEM N/A
- Revenue This Year
- RDVT $15.93
- CGEM N/A
- Revenue Next Year
- RDVT $13.85
- CGEM $278.37
- P/E Ratio
- RDVT $74.66
- CGEM N/A
- Revenue Growth
- RDVT 24.89
- CGEM N/A
- 52 Week Low
- RDVT $16.56
- CGEM $7.90
- 52 Week High
- RDVT $43.44
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- RDVT 41.59
- CGEM 30.05
- Support Level
- RDVT $37.89
- CGEM $8.01
- Resistance Level
- RDVT $40.88
- CGEM $9.16
- Average True Range (ATR)
- RDVT 1.32
- CGEM 0.46
- MACD
- RDVT -0.13
- CGEM -0.05
- Stochastic Oscillator
- RDVT 12.99
- CGEM 0.50
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in big data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.